Since the dawn of time, or at least the dawn of recombinant DNA technology (which for many of today's scientists is the same thing), investigators have been cloning and expressing heterologous proteins in a variety of different cells for a variety of different reasons. These range from cell biological studies looking at protein-protein interactions, post-translational modifications, and regulation, to lab-scale production in support of biochemical, biophysical and structural studies, to large scale production of potential biotherapeutics. In parallel, fusion-tag technology has grown-up to facilitate micro-scale purification (pull-downs), protein visualization (epitope tags), enhanced expression and solubility (protein partners, e.g. GST, MBP, TRX, SUMO), and generic purification (e.g.
Introduction
Advances in genomics, proteomics, and bioinformatics over the last thirty years have dramatically increased the use of recombinant DNA as a way to study proteins of interest for a variety of applications. Combined with affinity tagging, recombinant DNA techniques allow for the identification, modification, production, isolation, and purification of proteins from a range of host systems, including E. coli, yeast, plant, insect, and mammalian cell lines. On the other hand, production of recombinant proteins routinely encounters problems, including the formation of inclusion bodies, incorrect protein conformation, toxicity to the host cell, or low protein yield. These issues are most often addressed by changing expression hosts or through fusion of the protein of interest (POI) to a carrier protein (fusion tag). Located at either the N-or C-terminus of the protein of interest, fusion tags can improve protein solubility, achieve native protein folding, and increase total yield by improving expression and decreasing degradation.
Fusion tags may be used in tandem with affinity tags and other markers to improve detection, allow for protein secretion, and achieve greater total yield.
There are several published reviews on both affinity and fusion tags from the past several years (1; 2). While these reviews do an excellent job of describing the many tags and tag removal systems currently available, it can be difficult to determine which tags are the best candidates for specific applications. For example, it is estimated that 20-40% of eukaryotic proteins cannot be expressed in soluble form in prokaryotic hosts (3) . Given the variability of protein structures, many tags may have similar issues. This review, therefore, focuses on tags that are utilized in specific protein applications, including protein-protein interaction 'pull-down' assays, structure determination, e.g. X-ray crystallography, control and maintainenance of protein functionality, and large scale manufacturing. While this list is by no means exhaustive, we hope to provide insight on the prominent tags used for these applications.
Protein-protein interaction 'pull-down' assay
Proteins do not work in isolation, but instead interact in complex networks. When studying any one protein, the isolation of other proteins in its complex can have several uses, including the purification of one or more of the binding partners, or the identification of unknown binding partners. Protein complex immunoprecipitation (Co-IP) is a technique in which an antibody is bound to a known target protein, allowing this protein and other proteins that are bound to it to be precipitated, or 'pulled-down', out of solution and analyzed.
While effective, one of the problems with this technique is the difficulty in generating specific antibodies to the target protein. A solution is to clone the DNA of the target protein into an expression vector containing a fusion tag at either terminus of the protein. Depending on the tag, either affinity chromatography or an antibody can be used for capture of the complex. The use of affinity chromatography drastically speeds up the process of protein isolation and identification, and allows the same purification process to be used repeatedly. Additionally, this system can be used to increase the expression of the target protein beyond endogenous levels, potentially allowing more complete pull-down of the protein complex and providing greater amounts of specific bound proteins (4; 5).
The most common fusion tag used in pull-down assays is glutathione-Strasferase (GST). A 26 kDa protein from the parasitic helminth Schistosoma japonicum, GST binds with high affinity to glutathione (6) . When used as a fusion tag, GST can increase protein yield by allowing efficient initiation of translation (7) . GST has been used in a wide range of cell types, including E. coli (8) (9) (10) , yeast (11; 12) , plant (13; 14) , insect (15; 16) , and mammalian cells (17; 18) . For purification, the GST-protein fusion is bound to glutathione immobilized to a solid support such as agarose beads or magnetic particles.. The fusion construct is eluted by the addition of 10 mM reduced glutathione.
The target and associated proteins can be analyzed by standard methods such as SDS-PAGE or western blotting (19) . GST has been used as both an N-and C-terminal tag, and in many commercially available systems, a protease cleavage site is encoded between GST and the target protein, allowing removal of GST after purification.
One of the problems that can occur with GST-based pull down assays is the solubility of the binding protein. Specifically, proteins that are either highly hydrophobic or larger than 100 kDA tend to form insoluble aggregates and inclusion bodies when tagged with GST, rendering them inactive. To correct for this, detergents such as Triton X and CHAPS are often used in the purification process to enhance the solubility of the fusion complex. If the detergents disrupt the biological activity of the binding protein, a high salt buffer can also be used to encourage solubility (20) .
Another issue with GST is its propensity to dimerize. Native GST exists as a homodimer, and when fused with a target protein that can also oligomerize, the resulting fusion can form large complexes that are not easily eluted from the bound glutathione resin (21) . Strategies to prevent dimerization include modification of salt or pH, or the addition of a strong reducing agent such as dithiothreitol (DTT). Another tactic is to promote elution by the addition of extra free glutathione, or by switching the elution agent to S-butylglutathione, which has a 25-fold higher affinity for GST than does glutathione (22) . As in the case of insolubility above, several of these solutions may disrupt the functionality of the tagged protein, and some researchers have suggested that GST is not suitable for pull down assays of proteins that are known to oligomerize (7; 23) .
While the most common, GST is not the only tag that is used for pull-down assays. Technically, any affinity tag that can be fused to the target protein will work, and as the most widely used affinity tag in general, it comes as little surprise that polyhistidine tags (usually hexahistidine or His 6 ) are also popular for pull-down assays.
Although a His 6 tag does not offer increased expression or solubility levels, it is small (0.84 kDa), immunogenically inactive, and doesn't dimerize. Like GST, the His 6 tag may be attached to the target protein at either the N-or C-terminus, and most proteins are functional with the tag attached. Purification of His 6 -tagged fusions involves immobilized metal-affinity chromatography (IMAC), as the negatively charged histidine binds to the positively charged metal ions, most commonly Ni 2+ (24) . The fusion construct can be eluted with an imidazole gradient (either stepwise or linear) (25) . One disadvantage of imidazole elution is the observation that high imidazole concentrations have been found to remove metal ions from a variety of proteins leaving them inactive and possibly altering the nature of their protein-protein interactions (26) . Beyond both GST and His 6, a number of additional tags are used for pull-down assays, including Strep-tag (27) , and
Fc-fusions (28) , although these are seen in much lower overall numbers.
Tags for structural studies
Generation of good quality protein for structural studies, such as NMR spectroscopy, X-ray crystallography, and cryo-electron microscopy, places stringent demands on protein production. These approaches require multi-milligram quantities of protein at high purity and production techniques that minimize the use of detergents, chaotropes and reducing agents that might alter the final structure of the protein or prevent the formation of good quality diffracting crystals. While incorporating fusion tags can overcome some of these challenges by increasing yield, enhancing folding and streamlining purification, they can also create new obstacles. Multi-domain fusion proteins joined by a flexible linker may be less likely to form well-ordered, diffracting crystals or be too large for NMR studies. Strategies that require tag removal introduce challenges including optimization of cleavage conditions, added costs of proteases for tag removal, and failure to recover soluble or structurally intact protein after tag removal.
On balance however, the advantages of using fusion tags for producing proteins for structural studies outweigh the disadvantages, and fusion tags have been widely adopted as the method of choice for protein production for structural study. Over 75% percent of proteins produced for crystallization are expressed as fusion constructs (29) .
By far, His 6 tag is the most common fusion partner, being used in 60% of crystallographic studies (30) . The His 6 -tag's small size does not generally interfere with crystallization and its utility in nickel affinity chromatography facilitates simple and costeffective purification at the multi-milligram scale (31) . His 6 -tags do have certain disadvantages, however, as they are variably gluconoylated in E. coli (32) , which can lead to heterogeneity that is not conducive to crystal formation. While His 6 -tags have clearly been effective in structural studies, the Structural Genomics Center has estimated that up to 50% of all prokaryotic proteins are insoluble when expressed in E.
coli with a His-tag (33; 34), and additional studies suggest that this number is higher for eukaryotic proteins (35) (36) (37) .
Many large fusion tags, such as maltose binding protein (MBP) (38), glutathione S-transferase (GST) (39), thioredoxin (40), and small ubiquitin-like modifier (SUMO) (41), enhance solubility and, either directly or in combination with small affinity tags, simplify purification. Therefore, expression of target proteins as fusions with these tags is often used as a rescue strategy for difficult to express proteins (cf. (42)). In most cases, tags are proteolytically removed prior to crystallization by engineering endoprotease cleavage sites between the fusion tag and the protein of interest. The high homogeneity necessary for crystallization trials requires minimal non-specific or variable cleavage during tag removal. Thrombin, enterokinase (enteropeptidase) and Factor Xa, commonly used for tag removal, have historically shown spurious cleavage at sites distinct from the engineered site (43). In contrast, the viral proteases, tobacco etch virus (TEV) or human rhinovirus 3C protease, have a lower turnover, which results in fewer catalytic events at sub optimal cleavage sites and thus greater specificity (43).
However, the lower turnover requires that large quantities of protease are required for tag removal and increases costs of protein production particularly at the multi-milligram scale. While limited to removal of SUMO tags, SUMO proteases provide both high specificity and high efficiency (44). SUMO proteases specifically recognize the tertiary structure of the SUMO tag, a structure not found elsewhere in the proteome, rather than a linear peptide sequence, and cleave precisely at the C-terminus of the tag.
Furthermore, SUMO protease has a k cat ~25-fold higher than TEV making the SUMO tag/SUMO protease system an efficient and cost-effective option for structural work (45).
A growing number of cases are being documented where crystallization is performed with the intact fusion protein (reviewed in Smyth (3) GST has a number of properties that make it a good candidate for carrier-driven crystallization (39). GST's hydrophilic surface can improve the solubility of the protein of interest, GST fusions can be readily purified via glutathione resins, and finally, the structure of recombinant GST is known (66) . Several structures of small peptides and protein regulatory domains have been determined as GST fusions, including gp41 from HIV (60), the C-terminal fibrinogen gamma chain (53), the ankryn-binding domain of -Na/K ATPase (52), acute myelogenous leukemia-1 nuclear matrix targeting sequence (AML-1 NMTS) (51),aand DNA replication-related element-binding factor (DREF) (50). A further set of proteins has been crystallized but no structures have been reported, presumably because the fused fragment is disordered. The success of carrier-driven GST appears to be limited to date to protein fragments less than 100 amino acids (62) .
The use of GST presents added drawbacks in that it does not improve solubility in all cases (71) and it forms dimers (72; 73), which can lead to aggregation of certain targets.
MBP has also been used successfully in carrier-driven crystallization (3; 46) Like GST, MBP confers increased solubility to its fusion partner (71) and its crystal structure has been solved (63) (64) (65) . In addition, the C-terminus of MBP forms a solvent accessible -helix, which provides a rigid support for linking the protein of interest (3) . Although MBP provides a strategy for affinity purificationby amylose affinity chromatography, MBP-fusion proteins often fail to bind to the amylose resin in practice (31; 74; 75). 
Tags for functional activity
The need to generate functionally active proteins is a necessity of many studies, but is especially important when the protein in question is a potential therapeutic.
Conformational characteristics, including proper folding and solubility, are an essential component of functionally active proteins, and these can be improved by the presence of fusion tags (83) . On the other hand, the generation of a native N-terminus is also critical for functional activity, particularly among cytokines, small peptides, and cytotoxic proteins, presenting additional challenges for tag use. MBP has been used for the production of Human β-defensin 25 (hBD25) and Human β-defensin 28 (hBD28), but both required refolding steps to recover fusion protein from aggregates in purification (98; 103).
Additional tags have been more consistently successful in expressing antimicrobial peptides. Thioredoxin has been used to achieve high-yields of precursor peptides in the cytoplasm, perhaps because of its smaller size (11.8 kDa) (40). SUMO, also small in size (11.2 kDa), has also been used successfully in generating defensins and cathelicidins. In the production of Human -Defensin-4, 166 mg per 1 L fermentation was obtained after purification (104) . LL-37, regarded as the only cathelicidin-derived antimicrobial peptide found in humans(105), has been produced in conjunction with thioredoxin in a dual-tag expression (104; 106). Other functionally active proteins produced with SUMO include the antibacterial peptide CM4 (ABP-CM4) (107), the PnTx3-4 toxin isolated from spider venom (108) , and the antitumor-analgesic peptide (AGAP) purified from scorpion venom (108; 109).
Self-cleaving affinity tags
The use of self-splicing tags (inteins) for the purification of recombinant proteins was first described in 1997 (110; 111) by a group working at New England Biolabs. respectively. Again, these methodologies have not gained wide acceptance outside of the originators' laboratories. Perhaps the most well-developed of these approaches is that developed by Bryan's group (140) and marketed by BioRad, Inc. as the Profinity system. In this instance, the affinity tag is the prodomain of the bacterial enzyme
subtilisin. An engineered form of subtilisin, which binds with high affinity to this prodomain, is coupled to agarose for affinity purification. As with the two protease tags described above, cleavage is initiated by a small molecule, in this case fluoride.
Although less potent, the enzyme can be activated by other halide ions limiting their use in buffers. Another drawback of this self-cleaving system is the requirement for separate expression, purification, and conjugation of the mutant subtilisin which could make the system cost-prohibitive at large scale. With the other two protease-based systems, the enzyme is expressed as part of the fusion protein insuring that sufficient protease is always present.
Large scale manufacturing
Large scale protein manufacturing is often quite different from small scale research production. While protein production for research and development might typically involve a few liters of culture or less to obtain the desired amount of purified product, commercial production often requires bioreactors capable of holding several thousand liters each. The challenges of high quantity and low cost bioprocessing mean that affinity and fusion tags are not commonly used, due in part to the extra time and cost associated with tag removal and the subsequent purification steps at such large scales. Therefore, when a tag system is used, it must present clear advantages in production or to the therapeutic itself. Since Fc-domains are essentially a functional section of the final therapeutic, no cleavage step is necessary. In order for a fusion system that does undergo tag removal to be considered for larger scale protein expression, additional benefits must be present to offset the additional purification costs. One such system is SUMO. As previously mentioned, SUMO can increase both the yield and solubility of its fusion partner and cleavage of the tag is performed by a specific SUMO protease which leaves no additional amino acids behind that can disrupt therapeutic function. When combined with a His 6 or other affinity tag on both the SUMO tag and the protease, a simple purification scheme based on IMAC chromatography can be used, and current 
